Corbus Pharmaceuticals Holdings, Inc.CRBPNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +171.60% | +175.32% | +333.84% | +335.19% | +2.44% |
| Weighted Average Shares Diluted Growth | +171.60% | +175.32% | +333.84% | +335.19% | +2.44% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +352.47% | +451.35% | +11.28% | -17.70% | -33.29% |
| Book Value per Share Growth | +17716.10% | +0.00% | -69.79% | -79.68% | -40.23% |
| Debt Growth | -84.21% | -84.49% | -83.49% | -83.40% | -43.24% |
| R&D Expense Growth | +64.98% | +25.89% | +171.47% | +121.22% | +93.01% |
| SG&A Expenses Growth | +59.93% | +23.42% | +7.04% | +1.07% | -24.27% |